19hon MSN
Healthy returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s
Structure Therapeutics CEO Ray Stevens talked about the biotech’s path forward and his expectations for the future of the ...
Eli Lilly looks undervalued as earnings forecasts rise and GLP-1 catalysts near. Read the full analysis here of LLY stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback